Cargando…
Lonafarnib Is a Potential Inhibitor for Neovascularization
Atherosclerosis is a common cardiovascular disease that involves the build-up of plaque on the inner walls of the arteries. Intraplaque neovacularization has been shown to be essential in the pathogenesis of atherosclerosis. Previous studies showed that small-molecule compounds targeting farnesyl tr...
Autores principales: | Sun, Linlin, Xie, Songbo, Peng, Guoyuan, Wang, Jian, Li, Yuanyuan, Qin, Juan, Zhong, Diansheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390146/ https://www.ncbi.nlm.nih.gov/pubmed/25853815 http://dx.doi.org/10.1371/journal.pone.0122830 |
Ejemplares similares
-
Lonafarnib: First Approval
por: Dhillon, Sohita
Publicado: (2021) -
Correction to: Lonafarnib: First Approval
por: Dhillon, Sohita
Publicado: (2021) -
Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells
por: Arnold, Rouven, et al.
Publicado: (2021) -
Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells
por: Wang, Jialiang, et al.
Publicado: (2017) -
Discovery of Lonafarnib-Like Compounds: Pharmacophore
Modeling and Molecular Dynamics Studies
por: Rampogu, Shailima, et al.
Publicado: (2020)